Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease.

Trial Profile

Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Deferiprone (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacodynamics
  • Acronyms FAIR-PARK-I
  • Most Recent Events

    • 23 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Planned end date changed from 1 Nov 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 21 Oct 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top